Part 1
Part 2
Part 3
Part 5
Market Analysis and Insights: Global and United States CD47 (IAP) Market This report focuses on global and United States CD47 (IAP) market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global CD47 (IAP) market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, CD47 Monoclonal Antibody accounting for % of the CD47 (IAP) global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, Solid Tumor was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period. In United States the CD47 (IAP) market size is expected to grow from US$ million in 2021 to US$ million by 2028, at a CAGR of % during the forecast period 2022-2028. Global CD47 (IAP) Scope and Market Size CD47 (IAP) market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global CD47 (IAP) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028. For United States market, this report focuses on the CD47 (IAP) market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States. Segment by Type CD47 Monoclonal Antibody CD47 Double Antibody CD47 Fusion Protein Segment by Application Solid Tumor Lymphoma Others By Region North America United States Canada Europe Germany France U.K. Italy Russia Asia-Pacific China Japan South Korea India Australia China Taiwan Indonesia Thailand Malaysia Latin America Mexico Brazil Argentina Middle East & Africa Turkey Saudi Arabia UAE By Company Gilead Innovent Biologics Akeso, Inc Arch Oncology ImmuneOncia Therapeutics I-MAB Sorrento Therapeutics Zai Lab ImmuneOnco Hengrui Beijing Mab-works Hanxbio ALX Oncology Surface Oncology TG Therapeutics EpicentRx
1 Study Coverage
1.1 CD47 (IAP) Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million) Introduction
1.2 Global CD47 (IAP) Outlook 2017 VS 2022 VS 2028
1.2.1 Global CD47 (IAP) Market Size for the Year 2017-2028
1.2.2 Global CD47 (IAP) Market Size for the Year 2017-2028
1.3 CD47 (IAP) Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States CD47 (IAP) in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of CD47 (IAP) Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 CD47 (IAP) Market Dynamics
1.4.1 CD47 (IAP) Industry Trends
1.4.2 CD47 (IAP) Market Drivers
1.4.3 CD47 (IAP) Market Challenges
1.4.4 CD47 (IAP) Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 CD47 (IAP) by Type
2.1 CD47 (IAP) Market Segment by Type
2.1.1 CD47 Monoclonal Antibody
2.1.2 CD47 Double Antibody
2.1.3 CD47 Fusion Protein
2.2 Global CD47 (IAP) Market Size by Type (2017, 2022 & 2028)
2.3 Global CD47 (IAP) Market Size by Type (2017-2028)
2.4 United States CD47 (IAP) Market Size by Type (2017, 2022 & 2028)
2.5 United States CD47 (IAP) Market Size by Type (2017-2028)
3 CD47 (IAP) by Application
3.1 CD47 (IAP) Market Segment by Application
3.1.1 Solid Tumor
3.1.2 Lymphoma
3.1.3 Others
3.2 Global CD47 (IAP) Market Size by Application (2017, 2022 & 2028)
3.3 Global CD47 (IAP) Market Size by Application (2017-2028)
3.4 United States CD47 (IAP) Market Size by Application (2017, 2022 & 2028)
3.5 United States CD47 (IAP) Market Size by Application (2017-2028)
4 Global CD47 (IAP) Competitor Landscape by Company
4.1 Global CD47 (IAP) Market Size by Company
4.1.1 Top Global CD47 (IAP) Companies Ranked by Revenue (2021)
4.1.2 Global CD47 (IAP) Revenue by Player (2017-2022)
4.2 Global CD47 (IAP) Concentration Ratio (CR)
4.2.1 CD47 (IAP) Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of CD47 (IAP) in 2021
4.2.3 Global CD47 (IAP) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global CD47 (IAP) Headquarters, Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million) Type
4.3.1 Global CD47 (IAP) Headquarters and Area Served
4.3.2 Global CD47 (IAP) Companies Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into CD47 (IAP) Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States CD47 (IAP) Market Size by Company
4.5.1 Top CD47 (IAP) Players in United States, Ranked by Revenue (2021)
4.5.2 United States CD47 (IAP) Revenue by Players (2020, 2021 & 2022)
5 Global CD47 (IAP) Market Size by Region
5.1 Global CD47 (IAP) Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global CD47 (IAP) Market Size by Region (2017-2028)
5.2.1 Global CD47 (IAP) Market Size by Region: 2017-2022
5.2.2 Global CD47 (IAP) Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America CD47 (IAP) Market Size YoY Growth 2017-2028
6.1.2 North America CD47 (IAP) Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 United States
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific CD47 (IAP) Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific CD47 (IAP) Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 China Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.3 Europe
6.3.1 Europe CD47 (IAP) Market Size YoY Growth 2017-2028
6.3.2 Europe CD47 (IAP) Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America CD47 (IAP) Market Size YoY Growth 2017-2028
6.4.2 Latin America CD47 (IAP) Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa CD47 (IAP) Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa CD47 (IAP) Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 UAE
7 Company Profiles
7.1 Gilead
7.1.1 Gilead Company Details
7.1.2 Gilead Business Overview
7.1.3 Gilead CD47 (IAP) Introduction
7.1.4 Gilead Revenue in CD47 (IAP) Business (2017-2022)
7.1.5 Gilead Recent Development
7.2 Innovent Biologics
7.2.1 Innovent Biologics Company Details
7.2.2 Innovent Biologics Business Overview
7.2.3 Innovent Biologics CD47 (IAP) Introduction
7.2.4 Innovent Biologics Revenue in CD47 (IAP) Business (2017-2022)
7.2.5 Innovent Biologics Recent Development
7.3 Akeso, Inc
7.3.1 Akeso, Inc Company Details
7.3.2 Akeso, Inc Business Overview
7.3.3 Akeso, Inc CD47 (IAP) Introduction
7.3.4 Akeso, Inc Revenue in CD47 (IAP) Business (2017-2022)
7.3.5 Akeso, Inc Recent Development
7.4 Arch Oncology
7.4.1 Arch Oncology Company Details
7.4.2 Arch Oncology Business Overview
7.4.3 Arch Oncology CD47 (IAP) Introduction
7.4.4 Arch Oncology Revenue in CD47 (IAP) Business (2017-2022)
7.4.5 Arch Oncology Recent Development
7.5 ImmuneOncia Therapeutics
7.5.1 ImmuneOncia Therapeutics Company Details
7.5.2 ImmuneOncia Therapeutics Business Overview
7.5.3 ImmuneOncia Therapeutics CD47 (IAP) Introduction
7.5.4 ImmuneOncia Therapeutics Revenue in CD47 (IAP) Business (2017-2022)
7.5.5 ImmuneOncia Therapeutics Recent Development
7.6 I-MAB
7.6.1 I-MAB Company Details
7.6.2 I-MAB Business Overview
7.6.3 I-MAB CD47 (IAP) Introduction
7.6.4 I-MAB Revenue in CD47 (IAP) Business (2017-2022)
7.6.5 I-MAB Recent Development
7.7 Sorrento Therapeutics
7.7.1 Sorrento Therapeutics Company Details
7.7.2 Sorrento Therapeutics Business Overview
7.7.3 Sorrento Therapeutics CD47 (IAP) Introduction
7.7.4 Sorrento Therapeutics Revenue in CD47 (IAP) Business (2017-2022)
7.7.5 Sorrento Therapeutics Recent Development
7.8 Zai Lab
7.8.1 Zai Lab Company Details
7.8.2 Zai Lab Business Overview
7.8.3 Zai Lab CD47 (IAP) Introduction
7.8.4 Zai Lab Revenue in CD47 (IAP) Business (2017-2022)
7.8.5 Zai Lab Recent Development
7.9 ImmuneOnco
7.9.1 ImmuneOnco Company Details
7.9.2 ImmuneOnco Business Overview
7.9.3 ImmuneOnco CD47 (IAP) Introduction
7.9.4 ImmuneOnco Revenue in CD47 (IAP) Business (2017-2022)
7.9.5 ImmuneOnco Recent Development
7.10 Hengrui
7.10.1 Hengrui Company Details
7.10.2 Hengrui Business Overview
7.10.3 Hengrui CD47 (IAP) Introduction
7.10.4 Hengrui Revenue in CD47 (IAP) Business (2017-2022)
7.10.5 Hengrui Recent Development
7.11 Beijing Mab-works
7.11.1 Beijing Mab-works Company Details
7.11.2 Beijing Mab-works Business Overview
7.11.3 Beijing Mab-works CD47 (IAP) Introduction
7.11.4 Beijing Mab-works Revenue in CD47 (IAP) Business (2017-2022)
7.11.5 Beijing Mab-works Recent Development
7.12 Hanxbio
7.12.1 Hanxbio Company Details
7.12.2 Hanxbio Business Overview
7.12.3 Hanxbio CD47 (IAP) Introduction
7.12.4 Hanxbio Revenue in CD47 (IAP) Business (2017-2022)
7.12.5 Hanxbio Recent Development
7.13 ALX Oncology
7.13.1 ALX Oncology Company Details
7.13.2 ALX Oncology Business Overview
7.13.3 ALX Oncology CD47 (IAP) Introduction
7.13.4 ALX Oncology Revenue in CD47 (IAP) Business (2017-2022)
7.13.5 ALX Oncology Recent Development
7.14 Surface Oncology
7.14.1 Surface Oncology Company Details
7.14.2 Surface Oncology Business Overview
7.14.3 Surface Oncology CD47 (IAP) Introduction
7.14.4 Surface Oncology Revenue in CD47 (IAP) Business (2017-2022)
7.14.5 Surface Oncology Recent Development
7.15 TG Therapeutics
7.15.1 TG Therapeutics Company Details
7.15.2 TG Therapeutics Business Overview
7.15.3 TG Therapeutics CD47 (IAP) Introduction
7.15.4 TG Therapeutics Revenue in CD47 (IAP) Business (2017-2022)
7.15.5 TG Therapeutics Recent Development
7.16 EpicentRx
7.16.1 EpicentRx Company Details
7.16.2 EpicentRx Business Overview
7.16.3 EpicentRx CD47 (IAP) Introduction
7.16.4 EpicentRx Revenue in CD47 (IAP) Business (2017-2022)
7.16.5 EpicentRx Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer
List of Tables Table 1. CD47 (IAP) Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028) Table 2. CD47 (IAP) Market Trends Table 3. CD47 (IAP) Market Drivers Table 4. CD47 (IAP) Market Challenges Table 5. CD47 (IAP) Market Restraints Table 6. Global CD47 (IAP) Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 7. United States CD47 (IAP) Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 8. Global CD47 (IAP) Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 9. United States CD47 (IAP) Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 10. Top CD47 (IAP) Companies in Global Market, Ranking by Revenue (2021) Table 11. Global CD47 (IAP) Revenue by Player, (US$ Million), 2017-2022 Table 12. Global CD47 (IAP) Revenue Share by Player, 2017-2022 Table 13. Global CD47 (IAP) Companies Market Concentration Ratio (CR5 and HHI) Table 14. Global CD47 (IAP) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD47 (IAP) as of 2021) Table 15. Top Players of CD47 (IAP) in Global Market, Headquarters and Area Served Table 16. Companies Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million) Type Table 17. Date of International Companies Enter into CD47 (IAP) Market Table 18. Companies Mergers & Acquisitions, Expansion Plans Table 19. Top CD47 (IAP) Players in United States Market, Ranking by Revenue (2021) Table 20. United States CD47 (IAP) Revenue by Players, (US$ Million), 2020, 2021 & 2022 Table 21. United States CD47 (IAP) Revenue Share by Players, 2020, 2021 & 2022 Table 22. Global CD47 (IAP) Market Size by Region (US$ Million): 2017 VS 2022 VS 2028 Table 23. Global CD47 (IAP) Market Size by Region (2017-2022) & (US$ Million) Table 24. Global CD47 (IAP) Market Size Forecast by Region (2023-2028) & (US$ Million) Table 25. North America CD47 (IAP) Sales in Value by Country (2017-2028) & (US$ Million) Table 26. Asia Pacific CD47 (IAP) Sales in Value by Region (2017-2028) & (US$ Million) Table 27. Europe CD47 (IAP) Sales in Value by Country (2017-2028) & (US$ Million) Table 28. Latin Americaa CD47 (IAP) Sales in Value by Country (2017-2028) & (US$ Million) Table 29. Middle East and Africa CD47 (IAP) Sales in Value by Country (2017-2028) & (US$ Million) Table 30. Gilead Company Details Table 31. Gilead Business Overview Table 32. Gilead CD47 (IAP) Product Table 33. Gilead Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million) Table 34. Gilead Recent Development Table 35. Innovent Biologics Company Details Table 36. Innovent Biologics Business Overview Table 37. Innovent Biologics CD47 (IAP) Product Table 38. Innovent Biologics Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million) Table 39. Innovent Biologics Recent Development Table 40. Akeso, Inc Company Details Table 41. Akeso, Inc Business Overview Table 42. Akeso, Inc CD47 (IAP) Product Table 43. Akeso, Inc Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million) Table 44. Akeso, Inc Recent Development Table 45. Arch Oncology Company Details Table 46. Arch Oncology Business Overview Table 47. Arch Oncology CD47 (IAP) Product Table 48. Arch Oncology Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million) Table 49. Arch Oncology Recent Development Table 50. ImmuneOncia Therapeutics Company Details Table 51. ImmuneOncia Therapeutics Business Overview Table 52. ImmuneOncia Therapeutics CD47 (IAP) Product Table 53. ImmuneOncia Therapeutics Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million) Table 54. ImmuneOncia Therapeutics Recent Development Table 55. I-MAB Company Details Table 56. I-MAB Business Overview Table 57. I-MAB CD47 (IAP) Product Table 58. I-MAB Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million) Table 59. I-MAB Recent Development Table 60. Sorrento Therapeutics Company Details Table 61. Sorrento Therapeutics Business Overview Table 62. Sorrento Therapeutics CD47 (IAP) Product Table 63. Sorrento Therapeutics Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million) Table 64. Sorrento Therapeutics Recent Development Table 65. Zai Lab Company Details Table 66. Zai Lab Business Overview Table 67. Zai Lab CD47 (IAP) Product Table 68. Zai Lab Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million) Table 69. Zai Lab Recent Development Table 70. ImmuneOnco Company Details Table 71. ImmuneOnco Business Overview Table 72. ImmuneOnco CD47 (IAP) Product Table 73. ImmuneOnco Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million) Table 74. ImmuneOnco Recent Development Table 75. Hengrui Company Details Table 76. Hengrui Business Overview Table 77. Hengrui CD47 (IAP) Product Table 78. Hengrui Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million) Table 79. Hengrui Recent Development Table 80. Beijing Mab-works Company Details Table 81. Beijing Mab-works Business Overview Table 82. Beijing Mab-works CD47 (IAP) Product Table 83. Beijing Mab-works Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million) Table 84. Beijing Mab-works Recent Development Table 85. Hanxbio Company Details Table 86. Hanxbio Business Overview Table 87. Hanxbio CD47 (IAP) Product Table 88. Hanxbio Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million) Table 89. Hanxbio Recent Development Table 90. ALX Oncology Company Details Table 91. ALX Oncology Business Overview Table 92. ALX Oncology CD47 (IAP) Product Table 93. ALX Oncology Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million) Table 94. ALX Oncology Recent Development Table 95. Surface Oncology Company Details Table 96. Surface Oncology Business Overview Table 97. Surface Oncology CD47 (IAP) Product Table 98. Surface Oncology Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million) Table 99. Surface Oncology Recent Development Table 100. TG Therapeutics Company Details Table 101. TG Therapeutics Business Overview Table 102. TG Therapeutics CD47 (IAP) Product Table 103. TG Therapeutics Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million) Table 104. TG Therapeutics Recent Development Table 105. EpicentRx Company Details Table 106. EpicentRx Business Overview Table 107. EpicentRx CD47 (IAP) Product Table 108. EpicentRx Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million) Table 109. EpicentRx Recent Development Table 110. Research Programs/Design for This Report Table 111. Key Data Information from Secondary Sources Table 112. Key Data Information from Primary Sources List of Figures Figure 1. CD47 (IAP) Product Picture Figure 2. Global CD47 (IAP) Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 3. Global CD47 (IAP) Market Size 2017-2028 (US$ Million) Figure 4. United States CD47 (IAP) Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 5. United States CD47 (IAP) Market Size 2017-2028 (US$ Million) Figure 6. United States CD47 (IAP) Market Share in Global 2017-2028 Figure 7. CD47 (IAP) Report Years Considered Figure 8. Product Picture of CD47 Monoclonal Antibody Figure 9. Product Picture of CD47 Double Antibody Figure 10. Product Picture of CD47 Fusion Protein Figure 11. Global CD47 (IAP) Market Share by Type in 2022 & 2028 Figure 12. Global CD47 (IAP) Market Size by Type (2017-2028) & (US$ Million) Figure 13. Global CD47 (IAP) Market Share by Type (2017-2028) Figure 14. United States CD47 (IAP) Market Share by Type in 2022 & 2028 Figure 15. United States CD47 (IAP) Market Size by Type (2017-2028) & (US$ Million) Figure 16. United States CD47 (IAP) Market Share by Type (2017-2028) Figure 17. Product Picture of Solid Tumor Figure 18. Product Picture of Lymphoma Figure 19. Product Picture of Others Figure 20. Global CD47 (IAP) Market Share by Application in 2022 & 2028 Figure 21. Global CD47 (IAP) Market Size by Application (2017-2028) & (US$ Million) Figure 22. Global CD47 (IAP) Market Share by Application (2017-2028) Figure 23. United States CD47 (IAP) Market Share by Application in 2022 & 2028 Figure 24. United States CD47 (IAP) Market Size by Application (2017-2028) & (US$ Million) Figure 25. United States CD47 (IAP) Market Share by Application (2017-2028) Figure 26. North America CD47 (IAP) Market Size Growth Rate 2017-2028 (US$ Million) Figure 27. United States CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 28. Canada CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 29. Europe CD47 (IAP) Market Size Growth Rate 2017-2028 (US$ Million) Figure 30. Germany CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 31. France CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 32. U.K. CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 33. Italy CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 34. Russia CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 35. Asia-Pacific CD47 (IAP) Market Size Growth Rate 2017-2028 (US$ Million) Figure 36. China CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 37. Japan CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 38. South Korea CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 39. India CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 40. Australia CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 41. China Taiwan CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 42. Indonesia CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 43. Thailand CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 44. Malaysia CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 45. Latin America CD47 (IAP) Market Size Growth Rate 2017-2028 (US$ Million) Figure 46. Mexico CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 47. Brazil CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 48. Argentina CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 49. Middle East & Africa CD47 (IAP) Market Size Growth Rate 2017-2028 (US$ Million) Figure 50. Turkey CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 51. Saudi Arabia CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 52. UAE CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 53. Gilead Revenue Growth Rate in CD47 (IAP) Business (2017-2022) Figure 54. Innovent Biologics Revenue Growth Rate in CD47 (IAP) Business (2017-2022) Figure 55. Akeso, Inc Revenue Growth Rate in CD47 (IAP) Business (2017-2022) Figure 56. Arch Oncology Revenue Growth Rate in CD47 (IAP) Business (2017-2022) Figure 57. ImmuneOncia Therapeutics Revenue Growth Rate in CD47 (IAP) Business (2017-2022) Figure 58. I-MAB Revenue Growth Rate in CD47 (IAP) Business (2017-2022) Figure 59. Sorrento Therapeutics Revenue Growth Rate in CD47 (IAP) Business (2017-2022) Figure 60. Zai Lab Revenue Growth Rate in CD47 (IAP) Business (2017-2022) Figure 61. ImmuneOnco Revenue Growth Rate in CD47 (IAP) Business (2017-2022) Figure 62. Hengrui Revenue Growth Rate in CD47 (IAP) Business (2017-2022) Figure 63. Beijing Mab-works Revenue Growth Rate in CD47 (IAP) Business (2017-2022) Figure 64. Hanxbio Revenue Growth Rate in CD47 (IAP) Business (2017-2022) Figure 65. ALX Oncology Revenue Growth Rate in CD47 (IAP) Business (2017-2022) Figure 66. Surface Oncology Revenue Growth Rate in CD47 (IAP) Business (2017-2022) Figure 67. TG Therapeutics Revenue Growth Rate in CD47 (IAP) Business (2017-2022) Figure 68. EpicentRx Revenue Growth Rate in CD47 (IAP) Business (2017-2022) Figure 69. Bottom-up and Top-down Approaches for This Report Figure 70. Data Triangulation Figure 71. Key Executives Interviewed
Market Analysis and Insights: Global and United States CD47 (IAP) Market This report focuses on global and United States CD47 (IAP) market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global CD47 (IAP) market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, CD47 Monoclonal Antibody accounting for % of the CD47 (IAP) global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, Solid Tumor was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period. In United States the CD47 (IAP) market size is expected to grow from US$ million in 2021 to US$ million by 2028, at a CAGR of % during the forecast period 2022-2028. Global CD47 (IAP) Scope and Market Size CD47 (IAP) market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global CD47 (IAP) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028. For United States market, this report focuses on the CD47 (IAP) market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States. Segment by Type CD47 Monoclonal Antibody CD47 Double Antibody CD47 Fusion Protein Segment by Application Solid Tumor Lymphoma Others By Region North America United States Canada Europe Germany France U.K. Italy Russia Asia-Pacific China Japan South Korea India Australia China Taiwan Indonesia Thailand Malaysia Latin America Mexico Brazil Argentina Middle East & Africa Turkey Saudi Arabia UAE By Company Gilead Innovent Biologics Akeso, Inc Arch Oncology ImmuneOncia Therapeutics I-MAB Sorrento Therapeutics Zai Lab ImmuneOnco Hengrui Beijing Mab-works Hanxbio ALX Oncology Surface Oncology TG Therapeutics EpicentRx
USD 4350.00
USD 6525.00
USD 8700.00
Add to Cart
Buy Now
A comprehensive and in-depth analysis of current industry data on markets, competitors and suppliers.
In-depth research on key industry players and analysis of production and sales operations.
Objective forecasts of future trends in the industry.
Competition
Key players, new entrants,acquisitions, mergers and expansions,development trends and challenges.
Industry Analysis
Rawmaterial, application, product type, demand,supply,downstream, supply chain etc.
Market Size
Capacity, production, sales, revenue, price, cost etc.
Customized Information
We can offer customized survey and information to meet ourclient's need.
Fastest report delivery service
More than 17 years of vast experience
Operation for 24 * 7 & 365 days
In-depth and comprehensive analysis
Professional and timely after-sales service
Owns large database
A comprehensive and in-depth analysis of current industry data on markets, competitors and suppliers.
In-depth research on key industry players and analysis of production and sales operations.
Objective forecasts of future trends in the industry.
Competition
Key players, new entrants,acquisitions, mergers and expansions,development trends and challenges.
Industry Analysis
Rawmaterial, application, product type, demand,supply,downstream, supply chain etc.
Market Size
Capacity, production, sales, revenue, price, cost etc.
Customized Information
We can offer customized survey and information to meet ourclient's need.
Fastest report delivery service
More than 17 years of vast experience
Operation for 24 * 7 & 365 days
In-depth and comprehensive analysis
Professional and timely after-sales service
Owns large database
Add to Cart
Buy Now